| 000 | 01589 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250517012835.0 | ||
| 264 | 0 | _c20151106 | |
| 008 | 201511s 0 0 eng d | ||
| 022 | _a1473-4877 | ||
| 024 | 7 |
_a10.1185/03007995.2015.1008131 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMacalalad, Alexander R | |
| 245 | 0 | 0 |
_aThe epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas. _h[electronic resource] |
| 260 |
_bCurrent medical research and opinion _cMar 2015 |
||
| 300 |
_a537-45 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aBrentuximab Vedotin |
| 650 | 0 | 4 | _aDisease Management |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 |
_aHodgkin Disease _xepidemiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoconjugates _xtherapeutic use |
| 650 | 0 | 4 |
_aKi-1 Antigen _xmetabolism |
| 650 | 0 | 4 |
_aLymphoma, Large-Cell, Anaplastic _xepidemiology |
| 650 | 0 | 4 |
_aMolecular Targeted Therapy _xmethods |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aSex Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aMcAuliffe, Megan | |
| 700 | 1 | _aYang, Hongbo | |
| 700 | 1 | _aKageleiry, Andrew | |
| 700 | 1 | _aZhong, Yichen | |
| 700 | 1 | _aWu, Eric Q | |
| 700 | 1 | _aShonukan, Oluwatoyin | |
| 700 | 1 | _aBonthapally, Vijayveer | |
| 773 | 0 |
_tCurrent medical research and opinion _gvol. 31 _gno. 3 _gp. 537-45 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1185/03007995.2015.1008131 _zAvailable from publisher's website |
| 999 |
_c24543293 _d24543293 |
||